Status:
TERMINATED
Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Lung Cancer - Non Small Cell
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this trial is to determine whether Ipilimumab will prolong survival when compared to Pemetrexed in subjects with nonsquamous, non-small cell lung cancer.
Eligibility Criteria
Inclusion
- For additional information, please contact the BMS oncology clinical trial information service at 855-216-0126 or email MyCancerStudyConnect@emergingmed.com. Please visit www.BMSStudyConnect.com for more information on clinical trial participation.
- Non-Squamous, Non-Small Cell Lung Cancer
- Recurrent/Stage IV Non-small cell lung cancer (NSCLC)
- Eastern Cooperative Oncology Group (ECOG) 0 or 1
- Not progressing after 4 cycles of a platinum-based first line chemotherapy
Exclusion
- Brain Metastases (unless stable)
- Autoimmune Diseases
Key Trial Info
Start Date :
July 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2013
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT01471197
Start Date
July 1 2012
End Date
February 1 2013
Last Update
May 12 2014
Active Locations (13)
Enter a location and click search to find clinical trials sorted by distance.
1
Marin Specialty Care, Inc.
Greenbrae, California, United States, 94904
2
Medical And Surgical Specialists, Llc
Galesburg, Illinois, United States, 61401
3
Quincy Medical Group
Quincy, Illinois, United States, 62301
4
Montgomery Cancer Center
Mount Sterling, Kentucky, United States, 40353